샘플 요청 목록

 카트 문의
시장보고서
상품코드
1985891

세포치료용 인간 유래 원재료 시장 규모, 점유율, 동향 분석 : 제품별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report By Product, By End Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 8,885,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,378,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,365,000
카드담기
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세포치료용 인간 유래 원재료 시장 요약

세계의 세포치료용 인간 유래 원재료 시장은 2025년에 43억 7,000만 달러 규모라고 평가되며, 2033년까지 167억 9,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 18.44%로 확대할 것으로 전망되고 있습니다.

암, 당뇨병, 자가면역질환 등 만성질환의 유병률 증가, 재생의료 및 맞춤의료에 대한 수요 증가, 연구개발(R&D) 활동 활성화 및 투자 확대가 예측기간 중 세포치료제용 인체유래 원료 시장을 촉진할 것으로 예상됩니다.

자주 묻는 질문

  • 세포치료용 인간 유래 원재료 시장 규모는 어떻게 예측되나요?
  • 세포치료용 인간 유래 원재료 시장의 성장 요인은 무엇인가요?

목차

제1장 분석 방법·범위

제2장 개요

제3장 시장의 변동 요인·동향·범위

제4장 제품별 사업 분석

제5장 최종 용도별 사업 분석

제6장 지역별 사업 분석

제7장 경쟁 구도

KSA 26.04.24

Cell Therapy Human Raw Materials Market Summary

The global cell therapy human raw materials market was size valued at USD 4.37 billion in 2025 and is projected to reach USD 16.79 billion by 2033, expanding at a CAGR of 18.44% from 2026 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, & autoimmune disorders, the growing demand for regenerative and personalized medicines, rising R&D activities, and increasing investments are anticipated to boost the cell therapy human raw materials market over the forecast period.

Global Cell Therapy Human Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the cell therapy human raw materials market on the basis of products, end use, and region.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cell Culture Media
  • Cell Culture Sera
  • Cell Culture Supplements
    • Proteins
    • Growth Factors
    • Nucleotides
    • Other Supplements
  • Reagents & Buffers
  • Other Raw Materials
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutions
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. MARKET DRIVER ANALYSIS
      • 3.2.1.1. Rapid growth of the cell therapy pipeline
      • 3.2.1.2. Expansion of regenerative medicine and personalized medicine
      • 3.2.1.3. Growing prevalence of immune-related disorders
    • 3.2.2. MARKET RESTRAINT ANALYSIS
      • 3.2.2.1. Ethical concerns related to stem cell research
      • 3.2.2.2. High cost associated with the production and procurement of raw materials
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis
  • 4.2. Cell Culture Media
    • 4.2.1. Cell culture media market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.3. Cell Culture Sera
    • 4.3.1. Cell culture sera market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4. Cell Culture Supplements
    • 4.4.1. Cell culture supplements market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Proteins
      • 4.4.2.1. Proteins market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Growth Factors
      • 4.4.3.1. Growth factors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Nucleotides
      • 4.4.4.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Other Supplements
      • 4.4.5.1. Other supplements market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Reagents & Buffers
    • 4.5.1. Reagents & buffers market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Other Raw Materials
    • 4.6.1. Other raw materials market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. End Use Group Business Analysis

  • 5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis
  • 5.2. Biopharmaceutical & Pharmaceutical Companies
    • 5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.3. CROs & CMOs
    • 5.3.1. CROS & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4. Academic & Research Institutions
    • 5.4.1. Academic & research institutions market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Cell Therapy Human Raw Materials Share By Region, 2025 & 2033
  • 6.2. North America
    • 6.2.1. North America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Target Disease Prevalence
      • 6.2.2.5. U.S. Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Target Disease Prevalence
      • 6.2.3.5. Canada Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Target Disease Prevalence
      • 6.2.4.5. Mexico Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. UK Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. Germany Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. France Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Target Disease Prevalence
      • 6.3.5.5. Italy Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Target Disease Prevalence
      • 6.3.6.5. Spain Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Target Disease Prevalence
      • 6.3.7.5. Denmark Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Target Disease Prevalence
      • 6.3.8.5. Sweden Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Target Disease Prevalence
      • 6.3.9.5. Norway Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Japan Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. China Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. India Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. Australia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Thailand Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.7. South Korea
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. South Korea Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Brazil Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. Argentina Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. South Africa Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Saudi Arabia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Target Disease Prevalence
      • 6.6.4.5. UAE Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Target Disease Prevalence
      • 6.6.5.5. Kuwait Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position/Share Analysis, 2025
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Actylis
      • 7.4.3.1. Overview
      • 7.4.3.2. Product Benchmarking
      • 7.4.3.3. Strategic Initiatives
    • 7.4.4. ACROBiosystems
      • 7.4.4.1. Overview
      • 7.4.4.2. Product Benchmarking
      • 7.4.4.3. Strategic Initiatives
    • 7.4.5. STEMCELL Technologies
      • 7.4.5.1. Overview
      • 7.4.5.2. Product Benchmarking
      • 7.4.5.3. Strategic Initiatives
    • 7.4.6. Grifols, S.A.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Charles River Laboratories
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. RoosterBio, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Product Benchmarking
      • 7.4.8.3. Strategic Initiatives
    • 7.4.9. PromoCell GmbH
      • 7.4.9.1. Overview
      • 7.4.9.2. Product Benchmarking
      • 7.4.9.3. Strategic Initiatives
    • 7.4.10. Danaher
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. BioIVT
      • 7.4.11.1. Overview
      • 7.4.11.2. Product Benchmarking
      • 7.4.11.3. Strategic Initiatives
    • 7.4.12. GeminiBio
      • 7.4.12.1. Overview
      • 7.4.12.2. Product Benchmarking
      • 7.4.12.3. Strategic Initiatives
    • 7.4.13. Akron Biotech
      • 7.4.13.1. Overview
      • 7.4.13.2. Product Benchmarking
      • 7.4.13.3. Strategic Initiatives
    • 7.4.14. AllCells
      • 7.4.14.1. Overview
      • 7.4.14.2. Product Benchmarking
      • 7.4.14.3. Strategic Initiatives
    • 7.4.15. CGT Global
      • 7.4.15.1. Overview
      • 7.4.15.2. Product Benchmarking
      • 7.4.15.3. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제